

POLEWACZYK JAMES F
Form 4
February 19, 2013

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
POLEWACZYK JAMES F

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [IDXX]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

(Last) (First) (Middle)
ONE IDEXX DRIVE
(Street)

3. Date of Earliest Transaction (Month/Day/Year)
02/14/2013

____ Director
 Officer (give title below)
____ 10% Owner
____ Other (specify below)
Corporate Vice President

WESTBROOK, ME 04092

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|----------------------------------------------------|--------------------------------|-------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------|-----------------------------------|
| | | | | (A) or (D) | Price | | |
| Common Stock | 02/14/2013 | | M | 186 | A \$ 0 | 6,287 ⁽¹⁾ | D |
| Common Stock | 02/14/2013 | | M | 194 | A \$ 0 | 6,481 | D |
| Common Stock | 02/14/2013 | | M | 281 | A \$ 0 | 6,762 | D |
| Common Stock | 02/14/2013 | | M | 400 | A \$ 0 | 7,162 | D |
| Common Stock | 02/14/2013 | | M | 257 | A \$ 0 | 7,419 | D |

Edgar Filing: POLEWACZYK JAMES F - Form 4

Common Stock 02/14/2013 F 464 D \$ 91.68 6,955 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) | Amount or Number of Shares |
|--------------------------------------------|--------------------------------------------------------|--------------------------------------|----------------------------------------------------|--------------------------------|-----------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------|----------------------------|
| | | | | Code | V (A) (D) | Date Exercisable Expiration Date | Title | |
| Non-Qualified Stock Option (right to buy) | \$ 91.68 | 02/14/2013 | | A | 8,222 | <u>(2)</u> 02/13/2020 | Common Stock | 8,222 |
| Incentive Stock Option (right to buy) | \$ 91.68 | 02/14/2013 | | A | 1,090 | <u>(3)</u> 02/13/2020 | Common Stock | 1,090 |
| Restricted Stock Unit | <u>(4)</u> | 02/14/2013 | | A | 900 | <u>(4)</u> <u>(4)</u> | Common Stock | 900 |
| Restricted Stock Unit | <u>(5)</u> | 02/14/2013 | | M | 186 | <u>(5)</u> <u>(5)</u> | Common Stock | 186 |
| Restricted Stock Unit | <u>(6)</u> | 02/14/2013 | | M | 194 | <u>(6)</u> <u>(6)</u> | Common Stock | 194 |
| Restricted Stock Unit | <u>(7)</u> | 02/14/2013 | | M | 281 | <u>(7)</u> <u>(7)</u> | Common Stock | 281 |
| Restricted Stock Unit | <u>(8)</u> | 02/14/2013 | | M | 400 | <u>(8)</u> <u>(8)</u> | Common Stock | 400 |
| Restricted Stock Unit | <u>(9)</u> | 02/14/2013 | | M | 257 | <u>(9)</u> <u>(9)</u> | Common Stock | 257 |

Reporting Owners

Reporting Owner Name / Address Relationships

Reporting Owners

Edgar Filing: POLEWACZYK JAMES F - Form 4

Director 10% Owner Officer Other

POLEWACZYK JAMES F
ONE IDEXX DRIVE
WESTBROOK, ME 04092

Corporate Vice President

Signatures

Conan R. Deady, Attorney-in-Fact for James F.
Polewaczyk

02/19/2013

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 45 shares and 55 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 09/30/2012 and 12/31/2012, respectively.
- (2) Grant of options to buy shares of common stock becomes exercisable as to 1,863 shares on 02/14/2014 and 02/14/2015, 1,862 shares on 02/14/2016 and 02/14/2017, and the remaining 772 shares on 02/14/2018.
- (3) Grant of options to buy shares of common stock that vest on the fifth anniversary date (02/14/2018) of the grant.
- (4) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2014) of the date of grant.
- (5) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2013) of the date of grant.
- (6) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2012) of the date of grant.
- (7) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2011) of the date of grant.
- (8) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2010) of the date of grant.
- (9) Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary date (02/14/2009) of the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.